dc.contributorBinda, Oliver
dc.contributorFernandez Zapico, Martin Ernesto
dc.creatorRoque Moreno, Maria
dc.creatorVargas Roig, Laura Maria
dc.date.accessioned2020-05-22T20:42:19Z
dc.date.accessioned2022-10-15T02:20:48Z
dc.date.available2020-05-22T20:42:19Z
dc.date.available2022-10-15T02:20:48Z
dc.date.created2020-05-22T20:42:19Z
dc.date.issued2016
dc.identifierRoque Moreno, Maria; Vargas Roig, Laura Maria; Crosstalk between DNA methylation chromatin structure; Elsevier; 2016; 257-270
dc.identifier978-0-12-802389-1
dc.identifierhttp://hdl.handle.net/11336/105832
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4334486
dc.description.abstractRegulation of gene expression is the result of a functional crosstalk between multiple epigenetic pathways. DNA methylation is an epigenetic mark that is typically related to gene silencing. Changes in DNA methylation are associated with specific histone modifications (other members in the crosstalk), including methylation and acetylation in N-terminal tails. Interestingly, these posttranslational histone modifications do not occur at random and are a consequence of the regulated crosstalk with DNA methylation. DNA methylation enzymes direct the histone modification process in a reversible way. Alterations in the crosstalk between DNA and histone modifications can lead to disease, for example, cancer. In the tumorigenic progression, it is proposed that cancer cells may modify their gene expression profile through the accumulation of genetic and epigenetic alterations. These changes affect the pathways that control the cell cycle. At the DNA level, tumors usually present global hypomethylation and tumor suppressor gene hypermethylation. At the histone level, the crosstalk is altered, and mistargeted histone deacetylase activity causes pathological gene silencing. Given the functionally linked crosstalk, the development of drugs that inhibit their interaction would open a promising window for future cancer treatments.
dc.languageeng
dc.publisherElsevier
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/B978-0-12-802389-1.00014-9
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourceChromatin signaling and diseases
dc.subjectCANCER
dc.subjectCHROMATIN STRUCTURE
dc.subjectCROSSTALK
dc.subjectDNA METHYLATION
dc.titleCrosstalk between DNA methylation chromatin structure
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typeinfo:eu-repo/semantics/bookPart
dc.typeinfo:ar-repo/semantics/parte de libro


Este ítem pertenece a la siguiente institución